Why Incretin Mimetics Play a Crucial Role in the Treatment of Type 2 Diabetes
A supplement to Family Practice News supported by an educational grant from the Amylin-Lilly alliance. This supplement was jointly sponsored by the Center for Accredited Healthcare Education and International Medical Press.
This supplement was developed through interviews with the faculty.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 20.
Topic Highlights
• Challenges to Meeting Glycemic Targets in Type 2 Diabetes
• Efficacy of Incretin Mimetics
• Future Directions in Incretin Mimetic Therapy
• Expert Insights on Maintaining Glycemic Control
Faculty
Frank Svec, MD, PhD
Professor of Medicine
Chief, Section of Endocrinology
Louisiana State University Health Sciences Center
New Orleans Dr Svec has disclosed that he does not have any financial relationships to report. He discloses that he intends to discuss unlabeled uses of incretin mimetics and that he anticipates discussing investigational products in this educational activity.
Scott V. Joy, MD, CDE, FACP
Associate Clinical Professor of Medicine
Division of General Internal Medicine
Duke University School of Medicine
Chief of Clinical Services
Duke University Medical Center
Durham, N.C. Dr Joy is formal advisor to Eli Lilly and Company and Amylin Pharmaceuticals. He discloses that he intends to discuss unlabeled uses of incretin mimetics and that he anticipates discussing investigational products in this educational activity.
Target Audience
This activity has been designed to meet the educational needs of family practitioners and health care professionals who treat patients with type 2 diabetes.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
• summarize at least three challenges to meeting glycemic targets in patients with type 2 diabetes.
• describe at least three of the five mechanisms of action of incretin mimetics.
• discuss the appropriate clinical use of incretin mimetics.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Center for Accredited Healthcare Education (CAHE) and International Medical Press (IMP). The CAHE is accredited by the ACCME to provide continuing medical education for physicians.
The Center for Accredited Healthcare Education designates this educational activity for a maximum of 1.75 category 1 credits toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Term of Approval: December 2006 to December 31, 2007.
